Nicotine Replacement is one of 121 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
199 competitors in Lung Cancer
Keytruda
Imfinzi
Opdivo
Tagrisso
Yervoy
Beyfortus
Abraxane
Tecentriq
Imjudo
Alunbrig
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources